LUND, Sweden, June 30, 2022 /PRNewswire/ -- Immunovia today announced the PanDIA-1 study for the early detection of pancreatic cancer in newly onset type 2 diabetics is moving into the next phase. Samples with the associated clinical data have been transferred to Immunovia from Lund University Diabetes Center (LUDC). During the second half of 2022 the samples will be analyzed as the next phase of the development plan for this large risk group.
"We are entering into a decisive phase of the PanDIA study, aiming to give another substantial risk group for pancreatic cancer the ability to get access to early detection. The prevalence of diabetes is dramatically increasing worldwide, and newly diagnosed diabetics have an up to 8 times higher risk of being diagnosed with pancreatic cancer. It is imperative that we change the paradigm, offer those individuals an option to get tested and allow them to benefit from treatment options available if diagnosed early", said Philipp Mathieu, CEO and President of Immunovia AB.
Immunovia started PanDIA-1 in January 2018 and it is one of the largest, comprehensive prospective sample collections for early detection of pancreatic cancer in new onset type 2 diabetics. 6,000 samples have been collected from the same number of new onset diabetes patients, of which approximately 4,800 are above the age of 50 years. The samples were collected from new onset diabetic patients starting at the time of diabetes diagnosis over a 3-year period thereafter, which is the time span during which patients with new-onset diabetes type 2 have a dramatically higher risk of developing pancreatic cancer.
The Center for Disease Control and Prevention estimates more than 37 million Americans have diabetes and approximately 90-95% of them have type 2 diabetes.
For more information, please contact:Philipp MathieuCEO and Presidentphilipp.firstname.lastname@example.org
Tobias BülowSenior Director Investor Relations and Corporate Communicationstobias.email@example.com+46 736 36 35 74
The information was submitted for publication on June 30, 2022, at 08:30 am CET.
Immunovia AB is a diagnostic company with the vision to revolutionize blood-based diagnostics and increase survival rates for patients with cancer.
Our first product, IMMray™ PanCan-d is the only blood test currently available specifically for the early detection of pancreatic cancer. The test has unmatched clinical performance. Commercialization of IMMray™ PanCan-d started in August 2021 in the USA and IMMray™ PanCan-d is offered as a laboratory developed test (LDT) exclusively through Immunovia, Inc. For more information see: www.immunoviainc.com.
Immunovia collaborates and engages with healthcare providers, leading experts and patient advocacy groups globally to make this test available to all high-risk pancreatic cancer groups.
The USA, the first market in which IMMray™ PanCan-d is commercially available, is the world's largest market for the detection of pancreatic cancer with an estimated value of more than USD 4 billion annually.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For more information, please visit www.immunovia.com.
This information was brought to you by Cision http://news.cision.com
The following files are available for download: